IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a clinical site in its Phase 2 CALMA trial evaluating IGC-AD1 for Alzheimer’s agitation. Approximately 80% of targeted participants have completed the trial, moving toward database lock and topline analysis while enhancing patient access and data integrity.
IGC Pharma has added the Icahn School of Medicine at Mount Sinai in New York as a new clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease.
With approximately 80% of targeted participants having completed the trial, CALMA is advancing toward database lock and topline analysis, reflecting substantial enrollment progress and data readiness.
The Mount Sinai addition enhances patient access at a major metropolitan research center and supports site quality, data integrity and a more diverse patient cohort as the trial approaches final-stage execution.
IGC-AD1 is being tested in a randomized, double-blind, placebo-controlled design, with the company focusing on disciplined execution, patient engagement and preparation for a meaningful data readout that could inform future regulatory decisions.
